EC Number   |
Disease |
PubMed ID |
Title of Publication  |
Category |
Confidence Level |
|---|
   3.4.21.7 | Thrombosis |
27833372 |
|
therapeutic application
unassigned |
4
0 |
| 3.4.21.7 | Stroke |
34442198 |
"Hesitating and Puzzling": The Experiences and Decision Process of Acute Ischemic Stroke Patients with Prehospital Delay after the Onset of Symptoms. |
therapeutic application
unassigned |
3
0 |
| 3.4.21.7 | Thrombosis |
1532403 |
"Plasminogen steal" and clot lysis. |
diagnostic usage
ongoing research
therapeutic application
unassigned |
3
4
1
0 |
| 3.4.21.7 | Thrombophilia |
33275705 |
"TEG talk": expanding clinical roles for thromboelastography and rotational thromboelastometry. |
causal interaction
unassigned |
1
0 |
| 3.4.21.7 | Stroke |
11126912 |
16(R)-hydroxyeicosatetraenoic acid, a novel cytochrome P450 product of arachidonic acid, suppresses activation of human polymorphonuclear leukocyte and reduces intracranial pressure in a rabbit model of thromboembolic stroke. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
3
1
0 |
| 3.4.21.7 | Neoplasms |
15987715 |
1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. |
causal interaction
therapeutic application
unassigned |
4
2
0 |
| 3.4.21.7 | Prostatic Neoplasms |
11953871 |
213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. |
ongoing research
therapeutic application
unassigned |
4
3
0 |
| 3.4.21.7 | Neoplasms |
15781388 |
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
| 3.4.21.7 | Thrombosis |
15781388 |
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
| 3.4.21.7 | Ischemic Stroke |
32568648 |
3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
